Neuromodulation is focused as a new therapy for primary headache disorders.
Non–invasive neuromodulation devices are free from surgical risks and those costs are practical ranges in primary care settings. It is also important most of these devices are self–applicable after the appropriate introductions.
Transcutaneous supraorbital trigeminal neurostimulation (Cefaly) is widely used in Europe and United States, and clinical evidence for migraine management have been accumulated. I demonstrated our preliminary favorable results of Cefaly devices for Japanese migraine sufferers. Non–invasive vagus nerve stimulation (nVNS) has been approved in United States. Single–pulse transcranial magnetic stimulation (sTMS) is also expected to be a new device for chronic pain including migraine headache.
These non–invasive neuromodulation devices will open new avenues on the management of primary headaches including migraine.